Anti-IL6R role in treatment of COVID-19-related ARDS

J Transl Med. 2020 Apr 14;18(1):165. doi: 10.1186/s12967-020-02333-9.

Authors

Franco Maria Buonaguro¹, Igor Puzanov², Paolo Antonio Ascierto³

Affiliations

¹ Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy.
² Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
³ Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy. paolo.ascierto@gmail.com.

No abstract available

Keywords: ARDS; COVID-19; IL-6; SARS-CoV-2; Tocilizumab.

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Betacoronavirus*
COVID-19
Coronavirus Infections
Humans
Pandemics
Pneumonia, Viral
Respiratory Distress Syndrome*
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
tocilizumab